Perspective research of preliminarily diagnosed angioimmunoblastic T-cell lymphoma with dose-adjusted EPOCH regimen

Kaili Zhong; Hang SU; Xiubin Xiao; Jing Liu; Yun LU; Xilin Chen; Yong DA; Chunlei LU; Weijing Zhang

Return

Perspective research of preliminarily diagnosed angioimmunoblastic T-cell lymphoma with dose-adjusted EPOCH regimen

VernacularTitle:剂量调整的EPOCH方案治疗初治血管免疫母T细胞淋巴瘤的前瞻性研究
Author: Kaili ZHONG ; Hang SU ; Xiubin XIAO ; Jing LIU ; Yun LU ; Xilin CHEN ; Yong DA ; Chunlei LU ; Weijing ZHANG
Publication Type:Journal Article
Keywords: angioimmunoblastic T-cell lymphoma; EPOCH regimen; initial treatment; chemotherapy
From: Chinese Journal of Clinical Oncology 2014;(19):1229-1233
CountryChina
Language:Chinese
Abstract: Objective:The effect and side effect of the dose-adjusted EPOCH regimen were evaluated perspectively for the pre-liminarily diagnosed angioimmunoblastic T-cell lymphoma. Methods: Nine cases of untreated angioimmunoblastic T-cell lymphoma were diagnosed and enrolled in our department from September 2008 to September 2012. All patients received dose-adjusted EPOCH regimen as first-line chemotherapy. Results: The median age of 9 patients was 54 years. The male-to-female ratio was 2∶1. About 88.9%of all patients were at Ann Arbor stageⅢ/Ⅳ, and 77.8%presented with B symptoms. Anemia was found in 66.7%of 9 patients, and lactate dehydrogenase elevated in 55.6%of patients. After an average of 4.7 cycles of chemotherapy of dose-adjusted EPOCH regi-men, the complete remission rate was 22.2%, and the total response rate was 66.7%. With a median follow-up of 20 months, the 4-year progression-free survival rate was 11.1%, and the overall survival rate was 33.3%. The median survival time was 19 months. The most common adverse events of EPOCH chemotherapy were hematologic toxicity. Grades 3-4 neutropenia and thrombocytopenia were re-ported in 77.8%and 33.3%of patients. Febrile neutropenia was observed in 44.4%of patients. Non-treatment-related mortality was al-so noted. Conclusion: The results of our research showed no clear benefit of treating preliminarily diagnosed angioimmunoblastic T-cell lymphoma with dose-adjusted EPOCH regimen. The main adverse events were hematologic toxicity and could be tolerated.